MAM
CYCN icon

Meeder Asset Management’s Cyclerion Therapeutics CYCN Stock Holding History

Meeder Asset Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-37
Closed -$2K – 2137
2020
Q1 		$2K Buy
37
+34
+1,133% +$2.42K ﹤0.01% 2069
2019
Q4 		$0 Buy
+3
New +$280 ﹤0.01% 2285

Other funds holding CYCN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Meeder Asset Management's CYCN Position: Q2 2020 in Review

Meeder Asset Management sold out of Cyclerion Therapeutics (CYCN) in Q2 2020, closing a stake of 37 shares — an estimated $2K sold.

Meeder Asset Management first reported a position in CYCN in Q4 2019 and held it in 2 quarters. The position peaked at $2K in Q1 2020. 74 funds tracked by Wall St. Rank hold CYCN as of Q2 2020.

  • Meeder Asset Management reported no remaining Cyclerion Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Meeder Asset Management sold 37 Cyclerion Therapeutics shares in Q2 2020, an estimated $2K.
  • Meeder Asset Management first reported a position in Cyclerion Therapeutics in Q4 2019 and held it in 2 quarters.
  • Meeder Asset Management's Cyclerion Therapeutics position peaked at $2K in Q1 2020.
  • 74 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.